<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37294</article-id><article-id pub-id-type="doi">10.7554/eLife.37294</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-110973"><name><surname>Hieronymus</surname><given-names>Haley</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3171"><name><surname>Murali</surname><given-names>Rajmohan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6988-4295</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110974"><name><surname>Tin</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110975"><name><surname>Yadav</surname><given-names>Kamlesh</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86469"><name><surname>Abida</surname><given-names>Wassim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110976"><name><surname>Moller</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110977"><name><surname>Berney</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110966"><name><surname>Scher</surname><given-names>Howard</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110967"><name><surname>Carver</surname><given-names>Brett</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110968"><name><surname>Scardino</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110969"><name><surname>Schultz</surname><given-names>Nikolaus</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110970"><name><surname>Taylor</surname><given-names>Barry</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110971"><name><surname>Vickers</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110972"><name><surname>Cuzick</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1025"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4955-6475</contrib-id><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Pathology</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Epidemiology and Biostatistics</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Urology</institution>, <institution>Icahn School of Medicine at Mount Sinai</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Cancer Epidemiology, Population and Global Health</institution>, <institution>Kings College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">Department of Molecular Oncology</institution>, <institution>Queen Mary University of London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><institution content-type="dept">Genitourinary Oncology Service, Department of Medicine</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution content-type="dept">Department of Urology</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff9"><institution content-type="dept">Marie-Josée and Henry R Kravis Center for Molecular Oncology</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff10"><institution content-type="dept">Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine</institution>, <institution>Queen Mary University of London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff11"><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1519"><name><surname>Green</surname><given-names>Michael R</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>sawyersc@mskcc.org</email> (CS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>09</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e37294</elocation-id><history><date date-type="received"><day>05</day><month>04</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>08</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Hieronymus et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Hieronymus et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-37294-v1.pdf"/><abstract><p>The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is associated with recurrence of primary prostate cancer. Whether CNA burden is associated with prostate cancer survival or outcomes in other cancers is unknown. We analyzed the CNA landscape of conservatively treated prostate cancer in a biopsy and transurethral resection cohort, reflecting an increasingly common treatment approach. We find that CNA burden is prognostic for cancer-specific death, independent of standard clinical prognostic factors. More broadly, we find CNA burden is significantly associated with disease-free and overall survival in primary breast, endometrial, renal clear cell, thyroid, and colorectal cancer in TCGA cohorts. To assess clinical applicability, we validated these findings in an independent pan-cancer cohort of patients whose tumors were sequenced using a clinically-certified next generation sequencing assay (MSK-IMPACT), where prognostic value varied based on cancer type. This prognostic association was affected by incorporating tumor purity in some cohorts. Overall, CNA burden of primary and metastatic tumors is a prognostic factor, potentially modulated by sample purity and measurable by current clinical sequencing.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA193837</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000892</institution-id><institution>Prostate Cancer Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yadav</surname><given-names>Kamlesh</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA092629</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA155169</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Charles L Sawyers, Senior Editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files and reference materials. The conservative treatment TAPG copy number cohort array data was deposited in NCBI GEO under accession number GSE103665 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665, reviewer access token czwruyesnzqbbyn).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Hieronymus H</collab><collab>Taylor BS</collab><collab>Sawyers CL</collab></person-group><year iso-8601-date="2018">2018</year><source>Copy number alteration burden is a pan-cancer prognostic factor associated with metastasis and death in conservatively treated prostate cancer: TAPG1 CNA cohort aCGH data</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE103665)</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-37294-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>